

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI XDC CAYMAN INC.**

**藥明合聯生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2268)**

### **POSITIVE PROFIT ALERT**

This announcement is made by WuXi XDC Cayman Inc. (the “**Company**”, which together with its subsidiaries collectively as the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the year ended December 31, 2025, and other information currently available to the Board, the Group is expected to record remarkable growth in its key financial performance indicators. In particular, the growth rates of gross profit and adjusted financial measures are anticipated to significantly outpace its revenue growth, indicating further enhancement in the Group’s operational efficiency and profitability.

The Group is expected to record the following financial results for the year ended December 31, 2025:

- (1) Revenue: an increase of more than 45% as compared to the year ended December 31, 2024;

- (2) Gross profit: an increase of more than 70% as compared to the year ended December 31, 2024. The higher growth rate of gross profit relative to revenue demonstrates the effective optimization of the Group's products/services margins and its cost control capabilities;
- (3) Adjusted net profit before interest income and expense<sup>1</sup>: an increase of more than 45% as compared to the year ended December 31, 2024. Excluding the effect of foreign exchange movements, such growth rate is expected to exceed 65%, evidencing the strong profit growth momentum of the Group's core operating businesses; and
- (4) Net profit: an increase of more than 38% as compared to the year ended December 31, 2024, notwithstanding the adverse impact of foreign exchange and interest rate movements.

The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2025. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or audited by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors should refer to the annual results announcement of the Group for the year ended December 31, 2025, which is expected to be published on or about March 23, 2026.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi XDC Cayman Inc.**  
**Dr. Jincai LI**

*Executive Director and Chief Executive Officer*

Hong Kong, January 14, 2026

*As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincai LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.*

\* *For identification purpose only*

<sup>1</sup> The Group defines "adjusted net profit before interest income and expense" as net profit (an IFRS measure) after elimination of share-based compensation expense, interest income (including interest income from bank balances, short-term bank deposits and time deposits) and interest expense, which are considered non-operating items. It is a non-IFRS measure intended to supplement the Group's annual results prepared in accordance with IFRS and is not intended to be considered in isolation or as a substitute for the IFRS net profit of the Group.